Diabetic Macular Edema (DME) Clinical Trials

Find Diabetic Macular Edema (DME) Clinical Trials Near You

A Randomized, Double-Masked, Multicenter, 3-Arm, Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) MK-8748 Compared With Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME)

Status: Recruiting
Location: See all (33) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

Researchers are looking for new ways to treat diabetic macular edema (DME). In this trial, researchers want to learn if a trial medicine called MK-8748 can treat DME. An available standard (usual) treatment for DME is aflibercept. However, standard treatments such as aflibercept may not work for every person. The main goal of this trial is to learn if MK-8748 works as well as aflibercept to treat DME.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

⁃ The main inclusion criteria include but are not limited to the following:

• Has Type 1 or Type 2 diabetes mellitus and a hemoglobin A1c (HbA1c) of ≤12%

• Has a decrease in vision in the study eye determined by the Investigator to be primarily the result of diabetic macular edema (DME)

• For participants who are treatment-naïve for DME, the diagnosis must have been made within 9 months of screening. For all treatment-experienced participants, the first treatment should have been no longer than 3 years prior to the Screening visit

Locations
United States
Arizona
Associated Retina Consultants, Ltd ( Site 0084)
RECRUITING
Gilbert
California
Global Research Management ( Site 0066)
RECRUITING
Glendale
Retinal Consultants Medical Group ( Site 0013)
RECRUITING
Sacramento
Colorado
Retina Specialists of Colorado ( Site 0068)
RECRUITING
Denver
Connecticut
Retina Consultants ( Site 0065)
RECRUITING
Manchester
Florida
Vitreo Retinal Associates ( Site 0042)
RECRUITING
Gainesville
Retina Care Specialists ( Site 0095)
RECRUITING
Palm Beach Gardens
Retina Vitreous Associates of Florida ( Site 0034)
RECRUITING
Tampa
Florida Retina Institute ( Site 0105)
RECRUITING
Wildwood
Indiana
Midwest Eye Institute ( Site 0113)
RECRUITING
Carmel
Kansas
Retina Associates LLC ( Site 0024)
RECRUITING
Lenexa
Maryland
Mid Atlantic Retina ( Site 0062)
RECRUITING
Hagerstown
Retina Specialists ( Site 0074)
RECRUITING
Towson
Mississippi
Mississippi Retina Associates, P.A. ( Site 0061)
RECRUITING
Madison
North Carolina
North Carolina Retina Associates ( Site 0064)
RECRUITING
Wake Forest
New Jersey
Envision Ocular, LLC ( Site 0039)
RECRUITING
Bloomfield
New York
Retina Associates of Western NY, PC ( Site 0038)
RECRUITING
Rochester
South Carolina
Charleston Neuroscience Institute ( Site 0087)
RECRUITING
Bluffton
Palmetto Retina Center ( Site 0063)
RECRUITING
Florence
Charleston Neuroscience Institute ( Site 0022)
RECRUITING
Mt. Pleasant
Palmetto Retina Center ( Site 0014)
RECRUITING
West Columbia
Tennessee
Southeastern Retina Associates PC ( Site 0071)
RECRUITING
Johnson City
Southeastern Retina Associates PC ( Site 0018)
RECRUITING
Knoxville
Texas
Austin Retina Associates ( Site 0008)
RECRUITING
Austin
Retina Consultants of Texas ( Site 0001)
RECRUITING
Bellaire
Austin Retina Associates ( Site 0080)
RECRUITING
San Marcos
Retina Consultants of Texas ( Site 0029)
RECRUITING
Schertz
West Virginia
Retina Consultants ( Site 0104)
RECRUITING
Charleston
Other Locations
Argentina
Fundacion Zambrano ( Site 0402)
RECRUITING
Caba
Australia
Eyeclinic Albury-Wodonga ( Site 2204)
RECRUITING
Albury
Marsden Eye Specialists ( Site 2200)
RECRUITING
Parramatta
Sydney Retina Clinic and Day Surgery ( Site 2203)
RECRUITING
Sydney
United Kingdom
Bristol Eye Hospital ( Site 0902)
RECRUITING
Bristol
Contact Information
Primary
Toll Free Number
Trialsites@msd.com
1-888-577-8839
Time Frame
Start Date: 2026-08-27
Estimated Completion Date: 2029-10-31
Participants
Target number of participants: 960
Treatments
Experimental: MK-8748 Low Dose
Participants receive 5 initial administrations of MK-8748 low dose every 4 weeks (Q4W), then continue to receive MK-8748 low dose every 8 weeks (Q8W) until week 48. After week 48, participants will be treated at intervals determined based on individualized response to treatment, up to week 100.
Experimental: MK-8748 High Dose
Participants receive 5 initial administrations of MK-8748 high dose every 4 weeks (Q4W), then continue to receive MK-8748 high dose every 8 weeks (Q8W) until week 48. After week 48, participants will be treated at intervals determined based on individualized response to treatment, up to week 100.
Active_comparator: Aflibercept 2 mg
Participants receive 5 initial administrations of aflibercept 2 mg every 4 weeks (Q4W), then continue to receive aflibercept 2mg every 8 weeks (Q8W) until week 100.
Sponsors
Leads: Merck Sharp & Dohme LLC

This content was sourced from clinicaltrials.gov